Next Article in Journal
Diverse Mechanisms of Sp1-Dependent Transcriptional Regulation Potentially Involved in the Adaptive Response of Cancer Cells to Oxygen-Deficient Conditions
Next Article in Special Issue
Cancer Stem Cell Plasticity Drives Therapeutic Resistance
Previous Article in Journal
Oncogenic MicroRNAs: Key Players in Malignant Transformation
Previous Article in Special Issue
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy
Article Menu

Export Article

Open AccessArticle
Cancers 2016, 8(1), 1; doi:10.3390/cancers8010001

Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging

1
Department of Diagnostic Radiology & Radiation Oncology, Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
2
Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Hyogo 675-8555, Japan
3
Division of Radiology, Medical School Hospital, Kochi University, Nankoku, Kochi 783-8505, Japan
4
Department of Pharmacy, Medical School Hospital, Kochi University, Nankoku, Kochi 783-8505, Japan
*
Author to whom correspondence should be addressed.
Academic Editors: Zhe-Sheng (Jason) Chen and Dong-Hua (Hana) Yang
Received: 1 October 2015 / Revised: 16 December 2015 / Accepted: 16 December 2015 / Published: 22 December 2015
(This article belongs to the Special Issue Drug/Radiation Resistance in Cancer Therapy)
View Full-Text   |   Download PDF [3501 KB, uploaded 22 December 2015]   |  

Abstract

Background: We have developed a new radiosensitization treatment called Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Using KORTUC II, we performed breast-conserving treatment (BCT) without any surgical procedure for elderly patients with breast cancer in stages I/II or patients refusing surgery. Since surgery was not performed, histological confirmation of the primary tumor region following KORTUC II treatment was not possible. Therefore, to precisely evaluate the response to this new therapy, a detailed diagnostic procedure is needed. The goal of this study was to evaluate the therapeutic response to KORTUC II treatment in patients with stage I/II breast cancer using annual breast contrast-enhanced (CE) magnetic resonance imaging (MRI). Methods: Twenty-one patients with stage I/II breast cancer who were elderly and/or refused surgery were enrolled in this study. All patients underwent MRI prior to and at 3 to 6 months after KORTUC II, and then approximately biannually thereafter. Findings from MRI were compared with those from other diagnostic modalities performed during the same time period. Results: KORTUC II was well tolerated, with minimal adverse effects. All of 21 patients showed a clinically complete response (cCR) on CE MRI. The mean period taken to confirm cCR on the breast CE MRI was approximately 14 months. The mean follow-up period for the patients was 61.9 months at the end of October 2014. Conclusions: The therapeutic effect of BCT using KORTUC II without surgery could be evaluated by biannual CE MRI evaluations. Approximately 14 months were required to achieve cCR in response to this therapy. View Full-Text
Keywords: MRI; breast cancer; KORTUC; hydrogen peroxide; radiosensitizer; sodium hyaluronate MRI; breast cancer; KORTUC; hydrogen peroxide; radiosensitizer; sodium hyaluronate
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Yaogawa, S.; Ogawa, Y.; Morita-Tokuhiro, S.; Tsuzuki, A.; Akima, R.; Itoh, K.; Morio, K.; Yasunami, H.; Onogawa, M.; Kariya, S.; Nogami, M.; Nishioka, A.; Miyamura, M. Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging. Cancers 2016, 8, 1.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top